药物涂层球囊导管治疗良性前列腺增生相关下尿路症状的1年结果
EVEREST-I研究首次报告Optilume BPH导管系统治疗良性前列腺增生相关下尿路症状的1年结果。80例患者接受治疗,75例完成1年随访,81%的患者IPSS改善≥40%,IPSS、Qmax和QoL均持续改善,并发症发生率受器械直径显著影响。
要点
- Optilume BPH导管系统治疗1年后81%患者IPSS改善≥40%
- IPSS从22.3降至7.9,Qmax从10.9升至18.4 ml/s
- 术后并发症发生率受器械直径显著影响
核心结论
- Optilume BPH导管系统微创治疗安全,主观和客观指标均改善,获益迅速且持续至1年。
研究设计与样本
- EVEREST-I研究为首次1年结果报告,纳入80例男性患者,在拉丁美洲6个中心治疗,75例完成1年随访。
主要发现
- IPSS改善≥40%的患者比例在3个月和1年均为81%。
- IPSS从基线22.3改善至1年7.9,Qmax从10.9改善至18.4 ml/s,IPSS QoL从4.6改善至1.3。
- 术后并发症包括常见泌尿系统事件,并发症发生率受器械直径显著影响。
关键数值与推荐
- 纳入标准:年龄>50岁、中度至重度BPH相关LUTS、Qmax 5-15 ml/s、前列腺尿道长度30-55 mm、前列腺体积20-80 g。
- 主要终点为IPSS改善≥40%的受试者比例。
临床怎么用
- 该微创治疗可作为BPH相关LUTS患者的治疗选择,需进一步评估。
局限性
- 样本量80例,随访1年,需进一步评估该疗法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This is the first report of the 1-year outcomes of the EVEREST-I study evaluating the safety and efficacy of the Optilume® BPH Catheter System, a prostatic paclitaxel-coated balloon catheter system, for the treatment of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH). METHODS: Subjects were men >50 years old with moderate-to-severe LUTS secondary to BPH, peak urinary flow rate of 5-15 ml/s, prostatic urethra length 30-55 mm, and prostate volume 20-80 g. All were treated with the Optilume BPH Catheter System and followed at Foley removal, 2 weeks, 30 days, 3, 6, and 12 months after treatment. The primary endpoint was the proportion of subjects with ≥40% improvement in International Prostate Symptom Score (IPSS). The rate of post-procedural complications was evaluated. RESULTS: Eighty subjects were treated at six sites in Latin America and 75 completed the 1-year follow-up. The percent of subjects with an improvement ≥40% in IPSS from baseline was 81% at 3 months and 1 year. IPSS improved from 22.3 at baseline to 7.9 at 1 year, Qmax improved from 10.9 to 18.4 ml/s, and IPSS QoL improved from 4.6 to 1.3. Post-procedural complications included common urologic events and the rate of complications was significantly impacted by device diameter. CONCLUSIONS: Treatment with the minimally invasive Optilume BPH Catheter System is safe and showed subjective and objective improvements in LUTS. Benefits were rapid and persisted through 1 year. The initial results warrant further evaluation of this therapy as a treatment option for patients with LUTS related to BPH.
引用
- Kaplan SA, Pichardo M, Rijo E, et al. One-year outcomes after treatment with a drug-coated balloon catheter system for lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2021. PMID: 33833379. doi:10.1038/s41391-021-00362-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。